Investment Thesis Multiple catalysts in 1H20 (i.e. autologous CD38 CAR-T data share, possible announcement of Scilex IPO, possible announcement of collaborations / partnerships around Sorrento’s (SRNE) CD38 business unit with upfront cash consideration, possible favorable arbitration decision by April, possible RTX assignment of breakthrough status) have the potential to greatlyRead More →

Company Overview Marker Therapeutics (MRKR) was formed in October 2017 with a merger of privately held company Marker Cell Therapy, Inc. and TapImmune. Marker is a clinical-stage biotechnology company specializing in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies andRead More →

Company Thesis VistaGen Therapeutics (NASDAQ:VTGN) is a small-cap biotech company currently possessing 3 drug candidates in clinical trials for various psychiatric indications. Out of the 3 candidates, both PH94B indicated for social anxiety disorder and AV-101 indicated for major depressive disorder are extremely unlikely to become financially feasible investigations evenRead More →

Acer Therapeutics Inc. (NASDAQ:ACER) (“Acer” or the “Company”) is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet medical needs. Before markets opened on Tuesday, June 25, Acer announced that itRead More →

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Clinical Development Update Conference Call April 2, 2019 8:00 AM ET Company Participants McDavid Stilwell – Vice President, Corporate Communications & Investor Relations Sandy Macrae – Chief Executive Officer Stephane Boissel – Executive Vice President, Corporate Strategy Adrian Woolfson – Executive Vice President & Head ofRead More →